MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-30-2026
Sangamo Therapeutics Retained Earnings 2011-2026 | SGMO
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Sangamo Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.63 B | -1.5 B | -1.41 B | -1.15 B | -956 M | -778 M | -657 M | -563 M | -495 M | -441 M | -369 M | -329 M | -302 M | -276 M | -253 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -253 M | -1.63 B | -740 M |
Quarterly Retained Earnings Sangamo Therapeutics
| 2025-Q3 | 2025-Q2 | 2024-Q3 | 2024-Q2 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.59 B | -1.55 B | -1.48 B | -1.49 B | -1.35 B | -1.24 B | -1.13 B | -1.15 B | -1.1 B | - | -1 B | -956 M | -919 M | -871 M | -824 M | -778 M | -778 M | -778 M | -778 M | -657 M | -657 M | -657 M | -657 M | -563 M | -563 M | -563 M | -563 M | -495 M | -495 M | -495 M | -495 M | -441 M | -441 M | -441 M | -441 M | -369 M | -369 M | -369 M | -369 M | -329 M | -329 M | -329 M | -329 M | -302 M | -302 M | -302 M | -302 M | -276 M | -276 M | -276 M | -276 M | -253 M | -253 M | -253 M | -253 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -253 M | -1.59 B | -639 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B |  USA |
 |
Genfit SA
GNFT
|
-405 M | - | 2.54 % | $ 160 B |  France |
 |
Autolus Therapeutics plc
AUTL
|
-1.39 B | $ 1.34 | -3.6 % | $ 357 M |  Britain |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | USA |
 |
DBV Technologies S.A.
DBVT
|
-393 M | $ 20.13 | -1.13 % | $ 2.81 B | France |
 |
Alterity Therapeutics Limited
ATHE
|
-182 M | $ 3.65 | 1.3 % | $ 8.78 B |  Australia |
 |
Advaxis
ADXS
|
-197 M | - | -9.65 % | $ 45.9 M | USA |
 |
Dyadic International
DYAI
|
-93.5 M | $ 0.87 | - | $ 31.5 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-1.07 B | - | - | $ 86.2 M | USA |
 |
Aytu BioScience
AYTU
|
-334 M | $ 2.57 | -3.57 % | $ 16.1 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
Equillium
EQ
|
-216 M | $ 2.04 | 1.24 % | $ 117 M | USA |
 |
Aeterna Zentaris
AEZS
|
-335 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-63.5 M | - | -10.17 % | $ 12.2 K | USA |
 |
Fate Therapeutics
FATE
|
-1.53 B | $ 1.13 | -5.04 % | $ 134 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-1.13 B | - | - | $ 1.01 B | USA |
 |
Forte Biosciences
FBRX
|
-223 M | $ 26.57 | 0.49 % | $ 344 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-308 M | - | - | $ 26.5 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
-229 M | $ 6.14 | -4.36 % | $ 175 M | USA |
|
Foghorn Therapeutics
FHTX
|
-632 M | $ 4.74 | -2.87 % | $ 299 M | USA |
 |
AIkido Pharma
AIKI
|
-268 M | - | 1.93 % | $ 17.4 M | USA |
 |
Amicus Therapeutics
FOLD
|
-2.77 B | $ 14.46 | 0.03 % | $ 4.46 B | USA |
 |
Aptose Biosciences
APTO
|
-566 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Fulcrum Therapeutics
FULC
|
-594 M | $ 7.55 | -3.58 % | $ 478 K | USA |
 |
Galectin Therapeutics
GALT
|
-433 M | $ 2.25 | -12.3 % | $ 144 M | USA |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
-1.06 B | - | - | $ 867 M | Germany |
 |
BioNTech SE
BNTX
|
-410 M | $ 87.65 | -3.98 % | $ 27.2 B | Germany |
 |
Gilead Sciences
GILD
|
13.7 B | $ 138.19 | -1.38 % | $ 172 B | USA |
 |
Coherus BioSciences
CHRS
|
-1.38 B | $ 1.61 | -3.59 % | $ 189 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-265 M | $ 3.5 | -1.13 % | $ 236 B | Britain |
 |
Akouos
AKUS
|
-168 M | - | 0.23 % | $ 488 M | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
-200 M | $ 0.54 | 4.26 % | $ 503 K |  Israel |
 |
Genmab A/S
GMAB
|
7.11 B | $ 27.01 | -2.67 % | $ 17.2 B |  Danmark |
 |
Allakos
ALLK
|
-1.12 B | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-246 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
-6.7 B | $ 314.44 | -4.81 % | $ 41.2 B | USA |
 |
Gossamer Bio
GOSS
|
-1.44 B | $ 0.32 | -7.11 % | $ 73.1 M | USA |
 |
Grifols, S.A.
GRFS
|
619 M | $ 7.91 | -3.95 % | $ 6.83 B |  Spain |
 |
Alpine Immune Sciences
ALPN
|
-224 M | - | - | $ 2.17 B | USA |
 |
GT Biopharma
GTBP
|
-724 M | $ 0.42 | -6.49 % | $ 2.32 M | USA |
 |
Aileron Therapeutics
ALRN
|
-401 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-160 M | - | 4.14 % | $ 49.1 M | USA |
 |
Halozyme Therapeutics
HALO
|
54.8 M | $ 63.51 | 0.68 % | $ 7.61 B | USA |